PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Status:
Completed
Trial end date:
2021-02-25
Target enrollment:
Participant gender:
Summary
Protocol PEN-221-001 is an open-label, multicenter Phase 1/2a study evaluating PEN-221 in
patients with SSTR2 expressing advanced gastroenteropancreatic (GEP) or lung or thymus or
other neuroendocrine tumors or small cell lung cancer or large cell neuroendocrine carcinoma
of the lung.